Evidence map›Paper›PMID 36353740›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Tantalum-carbon-integrated nanozymes as a nano-radiosensitizer for radiotherapy enhancement.

Rui Li, Weiheng Zhao, Tingting Wu, Aifeng Wang, Qing Li, Ying Liu, Huihua Xiong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Tantalum-Based Nanomaterials: From Properties to Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Rui LiDepartment of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Weiheng ZhaoDepartment of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Tingting WuDepartment of Pharmacy, Henan Provincial People's Hospital, Department of Pharmacy of Centeral China Fuwai Hospital, Centeral China Fuwai Hospital of Zhengzhou University, Zheng Zhou, China.
Aifeng WangDepartment of Pharmacy, Henan Provincial People's Hospital, Department of Pharmacy of Centeral China Fuwai Hospital, Centeral China Fuwai Hospital of Zhengzhou University, Zheng Zhou, China.
Qing LiDepartment of Pharmacy, Henan Provincial People's Hospital, Department of Pharmacy of Centeral China Fuwai Hospital, Centeral China Fuwai Hospital of Zhengzhou University, Zheng Zhou, China.
Ying LiuDepartment of Pharmacy, Henan Provincial People's Hospital, Department of Pharmacy of Centeral China Fuwai Hospital, Centeral China Fuwai Hospital of Zhengzhou University, Zheng Zhou, China.
Huihua XiongDepartment of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Henan Provincial People's Hospital · CNTongji Hospital · CNZhengzhou University · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) plays a pivotal role in the comprehensive treatment of multiple malignant tumors, exerting its anti-tumor effects through direct induction of double-strand breaks (DSBs) or indirect induction of reactive oxygen species (ROS) production. However, RT resistance remains a therapeutic obstacle that leads to cancer recurrence and treatment failure. In this study, we synthesised a tantalum-carbon-integrated nanozyme with excellent catalase-like (CAT-like) activity and radiosensitivity by immobilising an ultrasmall tantalum nanozyme into a metal-organic framework (MOF)-derived carbon nanozyme through

Indexed as

hypoxiananozymeradiotherapyROStantalum

Identifiers

PMID36353740
PMCPMC9638097
OpenAlexW4307156292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.